Hyderabad-based biotech startup Transcell Biologics has announced a strategic investment from award-winning AI-first engineers, Quantiphi Inc, based in Boston. This investment aims to support expanding the client base and implementation of Digital Animal Replacement Technology (DART) as an Enterprise Solution for the global bio and pharmaceutical industry.

DART embodies an innovative leap forward in animal-free testing methods, fusing human MicroPhysiological Systems (hMPS) technology with AI/ML embedded in silico platform configurations to streamline and automate the bioassay processes producing statistically compliant reports. This innovative solution is designed to effectively test safety and efficacy concerns surrounding drugs and vaccines meant for human consumption.

The participation of the IAN Group in this strategic round underscores its commitment to supporting visionary entrepreneurs and investing in innovative startups that solve real-world problems through technology. 

Dr Subhadra Dravida, the Founder and CEO of Transcell Biologics, expressed that “DART represents a significant breakthrough in revolutionising drug and vaccine testing. This innovative approach offers a decentralised strategy without additional infrastructure requirements at end users' premises, enhancing the operating efficiency and accessibility of such validated testing procedures from their workstations.”

The implementation of DART has gained significant traction in Indian markets, with leading biopharmaceutical companies already adopting this Enterprise Solution in their high-impact programmes. Moreover, with the US FDA Modernization Act 2.0 phasing out animal-based testing in drug discovery and development, Transcell Biologics is poised to expand its client base in the USA, Europe, and Japan through its collaboration with Quantiphi.